Recent evidence also showed that GRP94 suppresses AKT activation in hepatocellular carcinoma in vivo and in vitro [13, 33], implying that AKT activation in PTEN-null driven EAC may also be impaired by the loss of GRP94. The gene discussed is AKT1; the disease is hepatocellular carcinoma.